PCM
BOLD

Prelude Capital Management’s Boundless Bio BOLD Stock Holding History

Prelude Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,624
Closed -$25.1K – 1441
2025
Q1 		$25.1K Hold
16,624
– – ﹤0.01% 1125
2024
Q4 		$48.2K Buy
16,624
+5,600
+51% +$16.3K ﹤0.01% 1148
2024
Q3 		$38.3K Buy
+11,024
New +$40K ﹤0.01% 1224

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's BOLD Position: Q2 2025 in Review

Prelude Capital Management sold out of Boundless Bio (BOLD) in Q2 2025, closing a stake of 16,624 shares — an estimated $25.1K sold.

Prelude Capital Management first reported a position in BOLD in Q3 2024 and held it in 3 quarters. The position peaked at $48.2K in Q4 2024. 44 funds tracked by Wall St. Rank hold BOLD as of Q2 2025.

  • Prelude Capital Management reported no remaining Boundless Bio position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 16,624 Boundless Bio shares in Q2 2025, an estimated $25.1K.
  • Prelude Capital Management first reported a position in Boundless Bio in Q3 2024 and held it in 3 quarters.
  • Prelude Capital Management's Boundless Bio position peaked at $48.2K in Q4 2024.
  • 44 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.